What are the benefits of the mechanism of action of linagliptin and what they mean to the practitioner? Review article
Article Sidebar
Published:
Mar 31, 2020
Keywords:
linagliptin, diabetes, pharmacotherapy
Main Article Content
Abstract
Linagliptin is a selective, reversible, competitive inhibitor of dipeptidyl peptidase (DPP-4), an enzyme involved in the inactivation of incretin hormones. Incretin hormones are involved in the physiological regulation of glucose homeostasis. Gliptins have no effect on gastric emptying, which significantly reduces the risk of gastrointestinal side effects. They have a neutral effect on body weight. DPP-4 inhibitors have no class effect and differ from one another in chemical structure, pharmacokinetic profile and some pharmacodynamic effects. Linagliptin is characterized by an optimal safety profile and low risk of interaction with other simultaneous used drugs.
Article Details
How to Cite
Sapilak , B. J., & Woroń , J. (2020). What are the benefits of the mechanism of action of linagliptin and what they mean to the practitioner?. Medycyna Faktow (J EBM), 13(1(46), 54-57. https://doi.org/10.24292/01.MF.0120.5
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Chisholm-Burns M.A., Schwinghammer T.L., Malone P.M. et al.: Pharmacotherapy Principles & Practice. McGraw-Hill Education, New York 2019.
2. Rosenthal L.D., Burchum J.R.: Pharmacotherapeutics for Advances Practice Providers. Elsevier, St Louis 2018.
3. DiPiro J.T., Talbert L.R., Yee G.C. et al.: Pharmacotherapy, a Pathophysiologic Approach. Mc Graw Hill Education, New York 2017.
4. Wirfs M.J.: Prescribing Drug Therapy. Springer Publishing Company, New York 2019.
5. Czupryniak L., Strojek K.: Diabetologia 2019. Via Medica, Gdańsk 2019.
6. Scheen A.J.: Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin. Pharmacokinet. 2010; 49: 573-588.
7. Blech S., Ludwig-Schwellinger E., Grafe-Mody E.U. et al.: The metabolism and disposition of the oral dipeptidyl peptidase-4inhibitor, linagliptin, in humans. Drug Metab. Dispos. 2010; 38: 667-678.
8. Lewin A.J., Arvay L., Liu D. et al.: Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes (abstract no. 821). 46th Annual Meeting of the EASD; 2010 Sep 20-24, Stockholm.
9. Gallwitz B., Rosenstock J., Emser A. et al.: Linagliptin is more effective than glimepiride at achieving a composite outcome of A1c target with no hypoglycaemia and no weight gain over 2 years in mildly hyperglycaemic T2D pts on metformin [abstract no. 1044-P]. 72nd Scientific Sessions of the American Diabetes Association; 2012 Jun 8-12, Philadelphia (PA).
10. Del Prato S., Taskinen M.R., Owens D.R. et al.: Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials. J. Diabetes Complications 2013; 27(3): 274-279. DOI: 10.1016/j.jdiacomp.2012.11.008.
11. Owens D.R., Swallow R., Dugi K.A. et al.: Efficacy and safety of linagliptin in persons type 2 diabetes inadequately controlled by a combination of metformin and type sulphonylurea: a 24-week randomised study. Diabetic Med. 2011; 28: 1352-1361.
12. McGuire D.K., Alexander J.H., Johansen O.E. et al.: Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation 2019; 139(3): 351-361. DOI: 10.1161/CIRCULATIONAHA.118.038352.
2. Rosenthal L.D., Burchum J.R.: Pharmacotherapeutics for Advances Practice Providers. Elsevier, St Louis 2018.
3. DiPiro J.T., Talbert L.R., Yee G.C. et al.: Pharmacotherapy, a Pathophysiologic Approach. Mc Graw Hill Education, New York 2017.
4. Wirfs M.J.: Prescribing Drug Therapy. Springer Publishing Company, New York 2019.
5. Czupryniak L., Strojek K.: Diabetologia 2019. Via Medica, Gdańsk 2019.
6. Scheen A.J.: Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin. Pharmacokinet. 2010; 49: 573-588.
7. Blech S., Ludwig-Schwellinger E., Grafe-Mody E.U. et al.: The metabolism and disposition of the oral dipeptidyl peptidase-4inhibitor, linagliptin, in humans. Drug Metab. Dispos. 2010; 38: 667-678.
8. Lewin A.J., Arvay L., Liu D. et al.: Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes (abstract no. 821). 46th Annual Meeting of the EASD; 2010 Sep 20-24, Stockholm.
9. Gallwitz B., Rosenstock J., Emser A. et al.: Linagliptin is more effective than glimepiride at achieving a composite outcome of A1c target with no hypoglycaemia and no weight gain over 2 years in mildly hyperglycaemic T2D pts on metformin [abstract no. 1044-P]. 72nd Scientific Sessions of the American Diabetes Association; 2012 Jun 8-12, Philadelphia (PA).
10. Del Prato S., Taskinen M.R., Owens D.R. et al.: Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials. J. Diabetes Complications 2013; 27(3): 274-279. DOI: 10.1016/j.jdiacomp.2012.11.008.
11. Owens D.R., Swallow R., Dugi K.A. et al.: Efficacy and safety of linagliptin in persons type 2 diabetes inadequately controlled by a combination of metformin and type sulphonylurea: a 24-week randomised study. Diabetic Med. 2011; 28: 1352-1361.
12. McGuire D.K., Alexander J.H., Johansen O.E. et al.: Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation 2019; 139(3): 351-361. DOI: 10.1161/CIRCULATIONAHA.118.038352.